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Vector-borne pathogens impact public health, animal production, and animal welfare. Research on arthropod 
vectors such as mosquitoes, ticks, sandflies, and midges which transmit pathogens to humans and economically 
important animals is crucial for development of new control measures that target transmission by the vector. While 
insecticides are an important part of this arsenal, appearance of resistance mechanisms is increasingly common. 
Novel tools for genetic manipulation of vectors, use of Wolbachia endosymbiotic bacteria, and other biological 
control mechanisms to prevent pathogen transmission have led to promising new intervention strategies, adding to 
strong interest in vector biology and genetics as well as vector–pathogen interactions. Vector research is therefore 
at a crucial juncture, and strategic decisions on future research directions and research infrastructure investment 
should be informed by the research community. A survey initiated by the European Horizon 2020 INFRAVEC-2 
consortium set out to canvass priorities in the vector biology research community and to determine key activities 
that are needed for researchers to efficiently study vectors, vector-pathogen interactions, as well as access the 
structures and services that allow such activities to be carried out. We summarize the most important findings 
of the survey which in particular reflect the priorities of researchers in European countries, and which will be of 
use to stakeholders that include researchers, government, and research organizations.
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pathogen transmission32,45–48 are suggesting promising 
new avenues of research into the control of vector-borne 
diseases. However, the specialized knowledge, cost, and 
infrastructure required to fully use new technologies can 
limit their dissemination and exploitation.
The European Union (EU) has identified access to spe-
cialized Research Infrastructures (RIs) offering unique 
research services to the international scientific commu-
nity as a key to producing high quality science. RIs are 
defined as
Tools for science … RIs offer unique research services 
to users from different countries, attract young people 
to science, and help to shape scientific communities 
… RIs may be ‘single-sited’ (a single resource at a 
single location), ‘distributed’ (a network of distrib-
uted resources), or ‘virtual’ (the service is provided 
electronically)49
Such RIs can be research facilities, resources, and 
related services. Within the Framework Programmes 
(FP) of the EU, RI projects support the improvement of 
high-level facilities for research and allow access to the 
facilities by researchers in Europe and eligible member 
states. A wide range of research disciplines have been 
targeted by RI projects, including physics, information 
science, earth science, and medicine. RI projects are not 
research networks, but rather are tasked to identify the 
key unique and rare RI necessary for a research com-
munity and organize them so that researchers at insti-
tutes lacking necessary infrastructure can benefit from 
Introduction
Vector-borne diseases (VBDs) such as malaria, dengue, 
and emerging threats such as chikungunya virus and Zika 
viruses have a major impact on human and animal health.1–4 
While established technologies such as drugs, vaccines, 
and insecticides are likely to remain major components 
of control strategies against new vector-borne disease 
threats, issues such as pathogen and vector diversity [see, 
e.g. Ref. 5], the challenges of vaccine and drug produc-
tion6–16 including shortages (e.g. in the case of yellow fever 
virus vaccine, see www.nc.cdc.gov/travel/news-announce-
ments/yellow-fever-vaccine-shortage-2016), resistance 
to drugs17–19, and insecticides [e.g. Ref. 20–26] require 
that research into vector biology and control is continu-
ously developed and strengthened. Finally, some vectors 
with mature reference genomes and toolkits, for example 
Anopheles gambiae, have become model research insects 
that now rival Drosophila melanogaster for questions on 
host–pathogen interactions, insect immunity, and popula-
tion genomics.
Developments over the last decade including 
high-throughput genomics and transcriptomics [with cor-
responding data repositories and analysis tools such as 
VectorBase27], population genetics,28–31 improved methods 
for genetic manipulation of arthropods,32–39 studies on the 
influence of the mosquito midgut microbiome on patho-
gen transmission,40–42 investigations on the impact of the 
insect-specific viruses on arbovirus transmission,43,44 and 
the use of Wolbachia endosymbiotic bacteria that prevent 
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it in order to expand the scope of their research. Thus, 
RIs are exceptional facilities that permit experiments 
that could not routinely be done without this structure. 
Use of RI facilities by external researchers is provided 
as so-called Transnational Access (TNA), with access 
costs reimbursed by the RI project, thus provided at no 
cost to the end user.
One such RI project under the 7th EU Framework 
Programme (FP7) was INFRAVEC, which focused on 
developing and providing research resources for insect 
vector biology from 2009 to 2014. INFRAVEC, which 
was constituted as an EC Starting Community under 
FP7, obtained the opportunity to continue as an advanced 
community (AC) called INFRAVEC-2 under the Horizon 
2020 framework. Conditions have changed since the 
inception of the FP7 INFRAVEC project, including the 
emergence and transmission of arboviruses in Europe 
and elsewhere, as well as widening the project scope to 
include vector-borne diseases of economically important 
animals and the most recently developed innovative tech-
nologies. Collecting updated information about the current 
and anticipated future infrastructure needs of the vector 
biology research community and other stakeholders is an 
important step to ensure that the services offered via TNA 
reflect actual needs of the advanced community. To our 
knowledge, there is no comparable recent source of such 
vector research community-needs information. Here, we 
present the findings of a survey of scientists and associated 
stakeholders in the field of vector biology or fields that are 
linked to vector biology such as pathogen studies, which 
will help to define priorities and requirements within 
INFRAVEC-2 but should also be of interest to govern-
ments, research organizations, and researchers in the field. 
Participation numbers suggest that in particular European, 
research priorities are reflected in the results, but the data 
can inform stakeholders worldwide.
Materials and methods
Survey structure
A questionnaire (S1 Table) was sent to organizational 
email lists (European Society for Vector Ecology; the 
journal Pathogens and Global Health; National Center 
of Expertise in Vectors (CNEV, France); CIRM-Italian 
Malaria Network; FP7 INFRAVEC mail list; International 
Meeting on Arboviruses and their Vectors mail list; 
BioInsectes; EU/DEVCO MEDILABSECURE network; 
WHO vector control working group), as well as to other 
lists available to the authors (institutional mailing lists, 
etc.). The questionnaire was sent as a URL link to the 
online form along with an explanatory note to scientists in 
the vector biology field and associated stakeholders. The 
questionnaire request was spontaneously retransmitted by 
an unknown number of recipients to organizational and 
other lists. Although not quantifiable, the degree of retrans-
mission suggests that exposure of the research community 
to the survey was high.
Briefly, the cover note explained the aims of the 
INFRAVEC-2 community, followed by a series of ques-
tions. The key areas covered by the survey are as follows: 
(1) vectors and vector-borne pathogens studied by survey 
participants, (2) research area (with several responses 
allowed), (3) infrastructures available at the respondents 
home institution including those for vector and animal 
research, (4) ease of access to vector research facilities 
outside the survey participants’ home institution, (5) 
infrastructures that participants would use, offered by the 
facilities at no cost to user, (6) identification of research 
priorities over the next 5–10 years, and (7) additional 
feedback. The survey was carried out from October to 
November 2015. Respondents were given the opportunity 
to provide their name and institution, although this was 
not required for completion of the questionnaire. However, 
all respondents (n = 211) identified themselves, indicating 
that repeat voting or vote stuffing is not a concern for 
interpretation of the results. All results shown here are 
anonymized, and no survey participant details published.
Results and discussion
In total, 211 responses were obtained (see S2 Table). 
Approximately 88% of respondents were from countries 
across Europe, with France, and then the UK providing 
the highest numbers of responses. This suggests that the 
results reflect a good overview of current priorities in 
European vector biology and vector research areas. Below 
we summarize and analyze the data obtained in the survey.
Research areas: arthropods and pathogens 
relevant to survey participants
Our goal was to obtain an overview of the research areas 
and work of survey participants, which are thus likely 
to guide their future research needs (S1 Table, Survey 
Questionnaire). First, respondents indicated vectors rel-
evant to their research as major or minor area of interest 
(Table 1). Aedes species mosquitoes were the top field, fol-
lowed by Anopheles and Culex species. The strong interest 
in aedine species may reflect the emergence of arboviruses 
such as chikungunya transmitted by Ae. aegypti and Ae. 
Table 1 Research areas and interests of the survey par-
ticipants. Numbers of responses are indicated as Major or 
Minor depending on vector listed, or in the category ‘Other’ 
which incorporates other vectors not specifically listed (se-
lection of responses shown)
Notes:  Vectors mentioned under ‘Other’ (selection of most men-
tioned): phlebotomines/sandflies33, fleas,13 tsetse flies,7 tria-
tomines,4 tabanids/horse flies.6
Arthropod Major Minor
Aedes spec. 102 38
Culex spec. 66 46
Anopheles spec. 79 42
Culicoides spec. 24 32
Ticks 55 44
Other 42 49
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and bluetongue.2,51,68,70,71 Given the historically important 
role of malaria research also in Europe (though much 
research is conducted overseas in affected areas, e.g. in 
Africa, often by groups working overseas and/or in col-
laboration with local teams), the overall importance in 
the vector field is not surprising. Of note was the impact 
of tick-borne pathogens in the category ‘Other’, and this 
is worth mentioning, especially with the impact of Lyme 
disease across Europe and North America72 and surge in 
interest in Crimean-Congo hemorrhagic fever virus.73,74
To describe their activities in more detail, we collected 
further data on the research areas of interest to the survey 
participants (Table 3). In general, vector biology describes 
the research of over half of the participants; however, 
this is a very broad term. Vector ecology, behavior, and 
control were also commonly reported. Of note, genetic 
modification and vector immunity remain relatively small 
fields despite important advances in these areas; these 
include CRISPR-Cas9-mediated genetic modification of 
mosquitoes75,76 and also deeper understanding of vec-
tor anti-pathogen responses.41,77–80 Interest may increase 
with better tools and access to new resources such as 
strains and facilities. The survey data showed that stud-
ies of pathogens either directly or within the context 
of host-pathogen or vector–pathogen interactions are a 
key area of research. This needs to be emphasized as it 
integrates disciplines such as virology, parasitology, cell 
biology, microbiology, and genetics into the vector field. 
Similarly, surveillance, diagnostics, and epidemiology 
were important areas and this (alongside vector control, 
behavior, and ecology) was an indication of the applied 
character of many activities in the field of vector-borne 
diseases.
Assessment of currently available facilities
Knowledge of availability and/or ease of access to research 
infrastructures is a key factor in the future planning of 
research activities. Survey participants were therefore 
asked to indicate their current organization’s current capa-
bilities. As shown in Table 4, survey participants indi-
cated a certain level of capacity to provide vectors but also 
material across the community. Moreover, facilities for 
biosafety level (BSL) 2 and 3 experiments with vectors, 
animals, and pathogens are available in several places. 
albopictus as well as the expansion of the latter species 
in Europe (and other areas) and acting as arbovirus vec-
tor.50–56 Despite their importance in the European context as 
major vectors of pathogens, comparatively little research 
is carried out on ticks that transmit viruses including tick-
borne encephalitis virus and Crimean-Congo hemorrhagic 
fever virus)57,58 and bacteria such as Borrelia.59,60 However, 
some recent studies on tick-borne pathogens in ticks or 
tick cells61–67 show that a knowledge base is present in 
Europe that can be built on. The same is true for Culicoides 
midges that transmit the emerging viruses Schmallenberg 
and bluetongue and thus became vectors of arboviruses in 
Europe.68–70 Indeed, studies on midge biology are carried 
out only in few places with specialist resources and exper-
tise such as the Pirbright Institute, most likely because 
Culicoides-borne pathogens have only recently emerged 
within the EU, and thus, there has been little incentive or 
resources to develop and maintain the skills and infrastruc-
ture needed for such research, such as laboratory colonies 
of Culicoides. This suggests that the European vector biol-
ogy community has some expertise but presently lacks 
sufficient opportunities and resources to expand research 
on these vectors. Among the category ‘Other’, comments 
by participants indicated phlebotomines/sand flies as a key 
area, with tsetse flies, fleas, triatomines, and tabanids/horse 
flies also mentioned.
We also quantified the major and minor interests of sur-
vey participants (Table 2). There was a notably strong indi-
cation of research interests in arboviruses, mainly affecting 
humans but livestock as well. These research interests and 
activities are likely due to the emergence and importance 
of arboviruses such as chikungunya, Zika, Schmallenberg, 
Table 2 Pathogens relevant to the survey participants. 
Numbers of responses are indicated as Major or Minor de-
pending on pathogen category listed, or in the category 
‘Other’ which incorporates other pathogens not specifically 
listed (selection of responses shown)
Pathogens mentioned under ‘Other’ (selection of most mentioned): 
Leishmania,15 trypanosomes,8 tick-borne pathogens23
Pathogen category Major Minor
Arboviruses, human 96 40
Arboviruses, livestock 44 45
Plasmodium spec. 66 31
Other 68 28
Table 3 Details of research areas relevant to survey participants. Numbers of responses are shown by research area, or in the 
category ‘Other’ which incorporates fields not specifically listed (selection of responses shown)
Other: evolution/population genetics, insecticide, etc. (few precise indications given).
Research area Response counts Research area Response counts
Vector biology 119 Host–pathogen interactions 102
Vector genetics/genomics 68 Vector–pathogen interactions 116
Vector immunity 32 Epidemiology 99
Vector behavior 77 Surveillance 96
Vector ecology 117 Diagnostics 69
Vector control 98 Other 29
Genetically modified arthropods 20
Pathogen biology 88
Genetically modified pathogens 28
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for the end user (Table 5). Although the questions below 
were originally aimed at potential European users, all 
answers were taken into account. Survey data show that 
in particular services and structures for arbovirus research 
would likely generate strong demand. Again this may be 
due to the surge in research in this field described above. 
Similarly, BSL2 and 3 studies on infected vectors and 
insecticides as well as behavior scored highly. Regarding 
technologies novel for the field, functional siRNA screens, 
and imaging of vectors did not score particularly high but 
this demand may increase in the future, particularly if 
facilities were available for access.
Vector genetics and genomics [see www.vectorbase.
org,27] but also studies of vector microbiomes [given their 
influence on mosquito infection with arboviruses and par-
asites40–42,81] are expanding fields. These research areas 
have strongly benefited from high-throughput sequenc-
ing techniques and bioinformatics. Survey participants 
were enthusiastic about developing insect vector-oriented 
infrastructures, services, and expertise in high-throughput 
genomics and bioinformatics, especially transcriptional 
profiling and genome and population analysis (Table 6).
The era of genomics has brought about much needed 
information on vector genomes [see, e.g. Ref. 82–84]. 
Genetic manipulation of genomes in basic biological stud-
ies of gene/sequence structure and function and applica-
tions based on genome manipulation [see, e.g. Ref. 85–87] 
are useful tools to maximize the value of this information, 
and for example, CRISPR-Cas9-mediated genome manipu-
lation is an important technical advance also for the vector 
field.75,88 We therefore asked survey participants about their 
interest in applying genome editing technologies within 
their work. As shown in Table 7, there was particularly 
strong interest in genetic manipulation of aedine mosqui-
toes. Culicoides midges seemed at present a less popular 
subject, probably at least in part because the community is 
small as mentioned above, as well as that the technologies 
have not yet been applied to this system or general issues 
with establishing colonies of important midge vector spe-
cies. Among the category ‘Other’, ticks stood out revealing 
a need to establish infrastructures for tick research.
Studies on vectors (infected, uninfected, or genetically 
modified) often include components that analyze behavior 
The concept of RI can be extended to reagent provision 
and has been successfully established by FP7 INFRAVEC 
and the European Virus Archive (http://www.european-vi-
rus-archive.com). This indicates an existing infrastructure 
base that can be developed and made available for research 
on vectors and pathogens on a wider basis (e.g. those who 
do not have immediate access to BSL 3 level insectaries 
but would require experiments to be carried out in such 
facilities) through communities such as INFRAVEC-2.
Assessment of infrastructure and service 
requirements
When survey participants were asked to indicate how 
many had requested access to insectaries at BSL2 or 3 
in other institutions, in total 62 positive responses were 
received. However, of these, 18 responses indicated that 
access could not be granted in a timely manner. This sug-
gests that inability to consistently access secure insectary 
facilities comprises a systematic weakness that impedes 
research on vector–pathogen interactions and may also 
explain the weaker interest in vector immunity studies, 
for example. The relevant secure insectary facilities exist 
in Europe (Table 4), and thus, a mutualized network of 
insectaries at BSL2 and 3 could resolve access limitations 
and promote elevated levels of vector research under BSL2 
and 3 conditions.
Access needs or provision of infected vectors or extracts 
from infected vectors were assessed, and participants were 
asked to indicate which pathogens or facilities/services 
would be of interest in the context of INRFAVEC-2 where 
these are free of cost (or the requirement for collaboration) 
Table 4 Research infrastructures and resources available 
to survey participants. Various types of structures relevant 
to vector and pathogen research are indicated
Available facilities and resources Response counts
Furnish vectors to external users 74
Furnish BSL2/BSL3 infected vectors/ex-
tracts to external users
32
BSL2 containment: arthropod infections 91
BSL3 containment: arthropod infections 60
Pathogen work in cell culture 128
BSL2 or BSL3 containment: small animal 
work
83
BSL2 or BSL3 containment: large animal 
work
27
Table 5 Infrastructure services (vector infection and vector–pathogen interactions) for the vector research community. Survey 
participants responded whether the services listed here (vector infection and vector–pathogen interactions) to study vector 
infections and vector–pathogen interactions would be of use if offered free of cost. Response counts are grouped into Likely, 
Not likely, or Possible use of the infrastructure/service
Category ‘Other needs’ included various Plasmodium species, Leishmania, tsetse flies, etc.
Infrastructure/service: vector infection and vector–pathogen interactions Likely Not likely Possible
Arboviruses 90 46 31
Plasmodium falciparum 36 77 33
Infected vector and insecticide studies 83 38 50
Behavioral studies with infected vectors 64 50 42
In vivo imaging with infected vectors 48 58 41
Functional siRNA screens of vector cells 35 68 36
Other needs 21 39 15
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be of interest to the community. Easily accessible qual-
ity-controlled vector colonies available from a European 
repository could be an important influence promoting 
comparability and reproducibility of experimental infec-
tions and other results across laboratories. Such newly 
initiated colonies would not suffer from some of the weak-
nesses of current colonies that are widely used by default, 
including bottlenecking and loss of genetic diversity, long-
term adaptation to fitness under insectary conditions with 
unknown consequences for traits related to vector compe-
tence, and even admixture of multiple species within the 
colony. New, rationally initiated colonies can for example 
be characterized for defined parameters such as compe-
tence for a given pathogen, defined genome sequences, 
and physiological properties to allow experiments to be 
better controlled. Similarly, vector systematics and col-
lections generated high interest. However, the practices 
of systematics may be at a juncture, because the techno-
logical capacity will soon be available to whole-genome 
sequence large numbers of unidentified individuals of a 
putative vector clade, and cluster them bioinformatically 
to determine phylogenetic relatedness. These results will 
need to be compared to existing collections, including 
voucher specimens. Perhaps surprisingly, new reference 
and cloned vector cell lines did not score highly but these 
and ecology. A further section of this survey therefore 
focused on a number of specific potential requirements in 
this area. As indicated in Table 8, the interest to work in 
field sites in endemic countries if access could be provided 
as well as standardized behavioral assays and bioassays 
for vectors generated strong positive responses. This sug-
gested a need for these in the vector research commu-
nity. Positive responses for large cage studies (controlled 
indoors or semi-controlled outdoors) were also strong con-
sidering that such applications are very specialized, and 
the facilities are rare. However, this illustrates the potential 
contribution of a RI project, because community mutual-
ization of rare infrastructures can allow access to state-
of-the-art facilities for researchers with occasional needs. 
In the future, the possibility to access such facilities may 
become stronger as more genetically modified vectors will 
be assessed in pre-release assays. Few positive responses 
for electrophysiology experiments were obtained, suggest-
ing that there is no major need for additional facilities 
beyond what is already in place.
Survey participants were also asked about their require-
ments for more specific vector-related data and research 
resources such as reference genomes, specific cell lines, 
and mosquito strains (Table 9). Results indicated that 
in particular, a bank of standard vector colonies would 
Table 6 Infrastructure services (vector genomics and bioinformatics) for the vector research community. Survey participants 
responded whether the services listed here (vector genomics and bioinformatics) would be of use if offered free of cost. Re-
sponse counts are grouped into Likely, Not likely, or Possible use of the infrastructure/service
Category ‘Other needs’ included proteomics, metabolomics.
Infrastructure/service: vector genomics and bioinformatics Likely Not likely Possible
Transcriptional profiling 75 42 53
Genome or population analysis 72 43 54
Bacterial microbiome profiling 45 63 41
Population or focused SNP genotyping 39 63 48
Other needs 10 41 8
Table 7 Infrastructure services (vector genome editing) for the vector research community. Survey participants responded 
whether vector genome editing would be of use if offered free of cost. Response counts are grouped into Likely, Not likely, or 
Possible use of the infrastructure/service
‘Other’ included ticks,17 phlebotomines,5 Culex spec., and tsetse flies (both 4).
Infrastructure/service: vector genome editing Likely Not likely Possible
Anopheles spec. 35 71 44
Aedes spec. 60 60 33
Culicoides spec. 20 85 17
Other 27 53 7
Table 8 Infrastructure services (vector ecology and behavior) for the vector research community. Survey participants re-
sponded whether specific services or infrastructures to study vector ecology and behavior would be of use if offered free of 
cost. Response counts are grouped into Likely, Not likely, or Possible use of the infrastructure/service
Very few responses to ‘Other needs’ given, for example, cage trials in Europe.
Infrastructure/service: vector ecology and behavior Likely Not likely Possible
Facilitated work at endemic country field sites 96 39 43
Electrophysiology 14 99 23
Standardized vector behavioral assays and bioassays 65 52 52
Large cage studies (controlled large indoor insectary) 64 61 46
Large cage studies (semi-controlled outdoor large cages) 46 77 40
Other needs 7 44 3
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contact potential respondents initially reflect activities in 
which the authors are involved in; however, the authors 
represent also a cross section of scientists involved in this 
research area. We thus expect this study to be relevant 
to stakeholders such as governments, research councils, 
and organizations but also researchers as priorities for 
future activities such as those planned by INFRAVEC-2 
are determined.
Supplemental data
The supplementary material for this paper is available 
online at http://dx.doi.10.1080/20477724.2016.1211475.
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may be of interest to smaller research areas such as virol-
ogists who carry out particular types of studies. Cell lines 
may be of less interest in malaria vector research where 
the biology is not consistent with simple cell models of 
Plasmodium–mosquito interaction. Despite high interest in 
Wolbachia to block pathogen transmission,47 generation of 
novel trans-infected vector strains was also not a priority. 
Finally, a small number of responses under ‘Other needs’ 
mentioned the importance of training.
Our survey specifically addressed training needs, com-
munity networking, and communication. As shown in 
Table 10, all suggestions – training in vector BSL2 and 3 
methods, training in bioinformatics and genomics, and sci-
entific communication by conferencing – were positively 
received by the survey participants. Clearly these are areas 
of need that should be developed as a real requirement 
within the vector research field.
Survey participants were also asked to give their opin-
ions in a text field on research priorities for vector biology 
over the next 5–10 years. Answers varied but some key 
areas were identified: (1) Vector interactions with hosts 
and pathogens, including vector competence and transmis-
sion; (2) insecticide resistance and novel insecticides; (3) 
ecology and behavior, including of infected vectors, intro-
duction of vectors, and mathematical modeling approaches 
to such questions, etc.; (4) vector control, novel control 
measures, and surveillance; (5) vaccines, including 
anti-vector vaccines; (6) vector genomics/genetics and 
bioinformatics. Although no survey can be complete, the 
data presented here yield a valuable qualitative picture 
of the needs and requirements in disease vector biology, 
especially of European scientists. It is clear that this survey 
cannot give a fully representative image of a wide and 
diverse community. The email lists which were used to 
Table 9 Infrastructure services (vector biology resources) for the vector research community. Survey participants responded 
whether specific resources for vector biology would be of use if offered free of cost. Response counts are grouped into Likely, 
Not likely, or Possible use of the infrastructure/service
Very few responses to ‘Other needs’ given, mainly mentioning training needs.
Infrastructure/service: vector biology resources Likely Not likely Possible
Bank of standard vector reference strains (genome and RNA sequenced) 85 34 54
Colonization of novel vector strains and species 76 45 53
Production of new reference vector cell lines (genome & RNA sequenced) 38 74 38
Production of cloned vector cell lines 39 75 37
Production of microbiome-free mosquitoes 28 82 40
Wolbachia-trans-infected vector strains 23 76 52
Vector systematics and collections 62 52 55
Other needs 5 44 3
Table 10 Infrastructure services (training and networking activities) for the vector research community. Survey participants 
responded whether specific services or infrastructures in the areas of training and networking activities would be of use if 
offered free of cost. Response counts are grouped into Likely, Not likely, or Possible use of the infrastructure/service
Very few responses to ‘Other needs’ given; one example: training of field workers and students in field identification.
Infrastructure/service: training and networking activities Likely Not likely Possible
Training in BSL2 and 3 vector infection and study techniques 96 30 51
Training in bioinformatics and genomic analysis 107 25 53
Conferencing 102 16 59
Other needs 8 32 7
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